Helen K. Tayton-Martin

Medicine · Health Sciences

3h-index1.2kcitations11works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(10), Immunotherapy and Immune Responses(8), Multiple Myeloma Research and Treatments(4), Monoclonal and Polyclonal Antibodies Research(2), Virus-based gene therapy research(1)

Publications11 total

Blazing a trail for commercial TCR T cell therapy
Cell and Gene Therapy Insights·2022
Commercial Business Models for Immunotherapies
Cell and Gene Therapy Insights·2018
Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming
Cancer Research·2015· 1 cited
511. Enhanced-Affinity NY-ESO-1-Specific T Cells Exhibit Extended Functionality without Exhaustion in a Pattern of Effector and Memory Programming in Multiple Cancer Indications
Molecular Therapy·2015Open Access
Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses
Blood·2013· 2 cited
Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
Journal for ImmunoTherapy of Cancer·2013· 1 citedOpen Access
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Blood·2013· 1.1k cited
Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma.
Cancer Research·2013
Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT)
Cytotherapy·2013· 2 cited
Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1
Blood·2012· 4 cited
Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT
Blood·2012· 12 cited

Frequent Co-authors

Edward A. Stadtmauer(9), Aaron P. Rapoport(9), Gwendolyn Binder-Scholl(9), Andrew B. Gerry(8), Alan Bennett(8), Bent K. Jakobsen(8), Michael Kalos(8), Carl H. June(8), Dan T. Vogl(8), Bruce L. Levine(7), Dominic Smethurst(7), Nick Pumphrey(7), Joanna E. Brewer(7), Brendan M. Weiss(7), Saul Yanovich(7), Ashraf Badros(6), Görgün Akpek(6), Naseem Kerr(6), Sunita Philip(6), Sandra Westphal(5)